Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Trinity Biotech

Trinity Biotech develops, manufactures and markets diagnostic test kits for the clinical laboratory and point-of-care... read more Featured Products: More products

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Syphilis Test Evaluated as Tool for Public Health Programs

By LabMedica International staff writers
Posted on 09 Nov 2016
A rapid commercial treponemal syphilis-screening test is a new tool for public health programs to combat increasing syphilis rates, specifically among persons without a prior syphilis infection.

The Syphilis Health Check (SHC) test can be performed by non-laboratorian healthcare personnel and results are available in 10 minutes and have recently received a Clinical Laboratory Improvement Amendments waiver.

Scientists at the Florida Department of Health (Tampa, FL, USA) in collaboration with The Centers of Disease Control and Prevention (CDC, Atlanta, GA, USA) evaluated the performance of SHC in comparison with treponemal and nontreponemal tests routinely used in its sexually transmitted disease (STD) clinic. More...
For this evaluation, patients seeking sexually transmitted diseases (STD) testing at the Florida Department of Health STD clinic in Escambia County during March 11 to April 21, 2016, were tested for syphilis using the SHC on blood specimens obtained by fingerstick; a venous blood specimen was drawn concurrently and submitted for treponemal and testing at the state public health laboratory.

Trep-Sure qualitative enzyme immunoassay (EIA) reference treponemal test was used as the standard for “true” positive or negative treponemal test results, when evaluating the SHC. The rapid plasma reagin (RPR) card for syphilis was also tested. The SHC was used to screen 202 patients for syphilis. Among these patients, 171 (85%) were nonreactive on all syphilis tests (SHC, EIA, and RPR), 26 (13%) had a reactive SHC, and five (2%) had a nonreactive SHC, but had one or more reactive tests at the state laboratory.

Among the 26 reactive SHCs, 10 (38%) had a reactive EIA (six had a reactive RPR), and 16 (62%) were not confirmed by EIA or RPR at the state laboratory. For the six reactive SHC patients with reactive EIA and reactive RPR, three were staged as secondary syphilis, one as primary syphilis, one as early latent syphilis, and one was a previously treated positive with no increase in titer since last testing. Among the five specimens that were reactive on other tests but SHC nonreactive, only one was both RPR (1:8 serum dilution) and EIA reactive. The sensitivity of SHC was 71.4% when compared with the Trep-Sure (EIA) reference treponemal test. The specificity of the SHC compared with the reference treponemal test was 91.5%. The study was published on October 28, 2016, in the journal Morbidity and Mortality Weekly Report.

Related Links:
Florida Department of Health
The Centers of Disease Control and Prevention

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.